Abstract:We would like to thank Dr. Liu et al. for the recognition of and comments on our recent study of the low allele frequency–blood-based tumor mutational burden (LAF-bTMB) as a superior overall survival (OS) predictor in NSCLC. The authors have supported our previous conclusion that allele frequency (AF) of mutations that represent tumor burden may interfere with bTMB estimation for the prediction of immunotherapy outcomes, and that LAF-bTMB on adjustment exhibited better predictive values. The authors have also proposed that the presence of minor subclones in the sample (as represented by the ratio of AF to maximum somatic AF) may also compromise the estimation of bTMB. On this hypothesis, the authors have provided a modified bTMB algorithm derived from the adjustment of both factors, which reveals no correlation with maximum somatic AF or tumor size and exhibits a seemingly satisfactory prediction of progression-free survival and OS outcomes with the data sets from POPLAR (N = 211) and OAK (N = 642) cohorts.1Gandara D.R. Paul S.M. Kowanetz M. et al.Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.Nat Med. 2018; 24: 1441-1448Crossref PubMed Scopus (676) Google Scholar We thank the authors for the additional information and explorations toward further refinement of bTMB. We agree that the investigations of subclones could provide more clues for the predictive value of bTMB; however, the authors did not present which one of the biomarkers (LAF-bTMB or modified bTMB) performed better as a predictor. To provide a clear picture of the biomarker performance, we have made direct comparisons between LAF-bTMB and the proposed modified bTMB in the same cohorts. The results revealed that, compared with LAF-bTMB, the modified bTMB has indeed narrowed down the population that may benefit from immunotherapy (from 181 of 853 [21.2%] down to 140 of 853 [16.4%]) (Fig. 1A). Notably, 41 nonoverlapped patients were identified as nonbeneficiaries of immunotherapy by the modified bTMB; whereas the beneficiaries identified by LAF-bTMB exhibited significantly longer OS from immunotherapy versus chemotherapy (hazard ratio, 0.41, 95% confidence interval: 0.20–0.87, log-rank p = 0.02) (Fig. 1B). In other words, the modified bTMB-high may be over-restricted and a non-negligible portion of patients who were suitable for immunotherapy may have been excluded. In addition, we have assessed the interaction effects between the modified bTMB and OS outcomes. Unlike LAF-bTMB (interaction p = 0.04 and 0.06 for OS in POPLAR and OAK, respectively),2Wang Z. Duan J. Wang G. et al.Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for patients with NSCLC treated with PD-(L)1 inhibitors.J Thorac Oncol. 2020; 15: 556-567Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar the interaction p value for the modified bTMB and OS did not reach statistical significance (0.10 in POPLAR; 0.09 in OAK), further supporting the better predictive value of LAF-bTMB over the modified bTMB in immunotherapy. Taken together, LAF-bTMB in our study serves as an optimal biomarker in the prediction of immunotherapy outcomes and the identification of patients who are most likely to benefit from immunotherapy. Future prospective studies and clinical utility are warranted.

Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Blood-based Tumor Mutational Burden As a Predictor of Clinical Benefit in Non-Small-cell Lung Cancer Patients Treated with Atezolizumab

Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Increased Blood-Based Intratumor Heterogeneity (bith) is Associated with Unfavorable Outcomes of Immune Checkpoint Inhibitors Plus Chemotherapy in Non-Small Cell Lung Cancer

P2.03b-092 Predictive and Prognostic Effect of Circulating Tumor Cells in Non-Small Cell Lung Cancer Treated with Targeted Therapy: Topic: Biomarkers

A Non-Linear Association Between Blood Tumor Mutation Burden and Prognosis in NSCLC Patients Receiving Atezolizumab

Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden As a Predictor of Overall Survival for Patients with NSCLC Treated with PD-(L)1 Inhibitors

PS01.55: IMpower010: Phase III Study of Atezolizumab Vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: Medical Oncology.

Maximum Somatic Allele Frequency In Combination With Blood-Based Tumor Mutational Burden To Predict The Efficacy Of Atezolizumab In Advanced Non-Small Cell Lung Cancer: A Pooled Analysis Of The Randomized Poplar And Oak Studies

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy

Ctdna-Profiling-based UBL Biological Process Mutation Status As a Predictor of Atezolizumab Response among TP53-Negative NSCLC Patients

Elucidation of the Application of Blood Test Biomarkers to Predict Immune-Related Adverse Events in Atezolizumab-Treated NSCLC Patients Using Machine Learning Methods

bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer

A Novel Algorithm to Redefine Blood-Based Tumor Mutational Burden for Optimized Prediction of Clinical Benefits from Immunotherapy.

Abstract 707: Combinatorial Assessment of Ctdna Release and Mutational Burden Predicts Clinical Outcome from Anti-Pd-(l)1 Therapies in Non-Small-cell Lung Cancer

Blood-based Tumour Mutation Index Act As Prognostic Predictor for Immunotherapy and Chemotherapy in Non-Small Cell Lung Cancer Patients

Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.

In Reply: A Modified Algorithm Adjusting Both High and Minor Allele-Frequency to Redefine Blood-Based Tumor Mutational Burden for Optimal Prediction of Clinical Benefits from Programmed Cell Death-Protein 1 Immunotherapy